98%
921
2 minutes
20
Objective: The objective of this study is to evaluate irritable bowel syndrome (IBS) as a risk factor for osteoporosis and osteoporotic fracture in Korean women after controlling for basic confounding factors and considering detailed demographic and clinical information.
Subjects And Methods: We performed a nationwide population-based retrospective cohort analysis and matched every IBS case with a non-IBS case at a 1:4 frequency ratio based on age. The population consisted of female patients with data in the Health Insurance Review and Assessment (HIRA) database from 2002 to 2010. To determine the risk of osteoporosis and osteoporotic fracture in IBS and non-IBS patients, hazard ratios (HRs) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression models, adjusting for confounding variables, such as the area of residence, health insurance type, and economic status.
Results: We identified 1,017,468 patients in the HIRA database with data from 2002 to 2010 who could potentially be included in the cohort. Among these, we identified 1,545 (11.4%) women (age >19 years) with newly diagnosed IBS (IBS group). Additionally, 6,180 patients without IBS and age-matched to the IBS group were selected. Cox modeling revealed that the crude HRs for osteoporosis and osteoporotic fractures in patients with IBS were 1.476 (95% CI, 1.241-1.754) and 1.427 (95% CI, 1.086-1.876), respectively.
Conclusion: Our data showed an increased incidence of osteoporosis and osteoporotic fractures in women with IBS compared with age-matched controls.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738912 | PMC |
http://dx.doi.org/10.1159/000517909 | DOI Listing |
Unlabelled: Dual-energy x-ray absorptiometry (DXA)-derived areal bone mineral density (BMD) remains the clinical standard for assessing osteoporosis risk, yet it fails to identify over 75% of individuals who sustain fragility fractures. Direct in vivo mechanical assessment of cortical bone strength may address this diagnostic gap by capturing structural and material properties that govern whole-bone strength but are not reflected by BMD. We conducted a multicenter case-control study with cross-sectional assessment to compare ulna flexural rigidity, a biomechanical property correlated with whole-bone strength (R² ≈ 0.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Orthopaedics and Traumatology, Vienna Healthcare Group, Clinic Donaustadt, Vienna, Austria.
Background: The incidence of osteoporosis and osteoporotic fragility fractures is increasing due to demographic changes. Therefore, early diagnosis is desirable in order to preserve bone health and prevent low-trauma fractures. Opportunistic screening for osteoporosis by frequently performed computed tomography scans could offer a potential solution.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Department of Spine Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Electronic address:
Background: Bone remodeling constitutes an intricate physiological process essential for maintaining skeletal integrity. Hyperactivation of osteoclastogenesis precipitates excessive resorption of osseous tissue, consequently engendering osteoporotic pathology. The formulation of effective anti-resorptive therapeutic modalities remains a potential strategy in the clinical management of osteoporosis.
View Article and Find Full Text PDFGlobal Spine J
September 2025
Department of Orthopaedic, Peking University First Hospital, Beijing, China.
Study DesignProspective Cohort Study.ObjectiveTo compare the effectiveness and safety of perioperative denosumab, bisphosphonates, and a control group in promoting lumbar fusion after midline lumbar fusion (MIDLF) surgery in patients with osteopenia or osteoporosis.MethodsThis prospective cohort study enrolled 54 patients with osteopenia or osteoporosis undergoing MIDLF surgery.
View Article and Find Full Text PDFUnlabelled: Initiating osteoporosis medication within 3 months after fracture reduces secondary fractures, particularly hip fractures, in individuals aged ≥ 75 years. This finding highlights the importance of early and sustained treatment in older populations.
Purpose: To evaluate the efficacy of initiating osteoporosis medication within 3 months after a fracture and continuing it for at least 6 months in preventing secondary fractures among individuals aged ≥ 75 years.